Press release 📈 Stocks 🌍 United States

Genezen Partners With InterAct Therapeutics to Advance AAV8 Gene Therapy

Genezen expands its CDMO pipeline through a new partnership with InterAct Therapeutics, aiming to scale manufacturing for advanced AAV8-based anti-metastasis gene therapies.

📅 October 5, 2026 🕐 1 min read

1 assets impacted. Net bias: 1 Bullish, 0 Bearish, 0 Neutral. Strongest signal: Genezen ↑ 3/10 (55% confidence).

📊 Affected Assets (1)

Genezen

Bullish 🤖 55%

📆 Mid-term 🌍 US · Explicit

Genezen announced a partnership with InterAct Therapeutics to advance AAV8-based gene therapy, expanding its CDMO pipeline and validating its manufacturing capabilities.

🎯 Key Takeaways

Genezen will provide CDMO manufacturing support for InterAct Therapeutics' AAV8-based gene therapy platform.
The partnership focuses on advancing innovative treatments designed to target and inhibit cancer metastasis.

📝 Executive Summary

Genezen has entered a strategic partnership with InterAct Therapeutics to accelerate the development of AAV8-based gene therapies. This collaboration leverages Genezen's CDMO manufacturing expertise to support InterAct's proprietary platform, which focuses on targeting metastatic cancer cells.

❓ FAQ

What is the primary goal of the partnership between Genezen and InterAct Therapeutics?

The collaboration aims to advance the development and manufacturing of AAV8-based gene therapies designed to target metastatic cancer.

📰 Related Articles

🏷️ Tags

📰 Source

🔗 View Original Article